{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:17:30Z","timestamp":1783095450017,"version":"3.54.6"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.yrtph.2022.105210","type":"journal-article","created":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T19:14:38Z","timestamp":1654974878000},"page":"105210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Physiologically based pharmacokinetic combined JAK2 occupancy modelling to simulate PK and PD of baricitinib with kidney transporter inhibitors and in patients with hepatic\/renal impairment"],"prefix":"10.1016","volume":"133","author":[{"given":"Zhongjian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongying","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huining","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guopeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3439-010X","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.yrtph.2022.105210_bib1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40265-018-0908-4","article-title":"Baricitinib: a review in rheumatoid arthritis","volume":"78","author":"Al-Salama","year":"2018","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.yrtph.2022.105210_bib2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jsps.2019.01.012","article-title":"Nano-encapsulation and characterization of baricitinib using poly-lactic-glycolic acid co-polymer","volume":"27","author":"Ansari","year":"2019","journal-title":"Saudi Pharmaceut. J."},{"issue":"12","key":"10.1016\/j.yrtph.2022.105210_bib3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s11095-020-02964-z","article-title":"Physiologically based pharmacokinetic models of probenecid and furosemide to predict transporter mediated drug-drug interactions","volume":"37","author":"Britz","year":"2020","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.yrtph.2022.105210_bib5","first-page":"20","article-title":"Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts","author":"Dagli-Hernandez","year":"2021","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.yrtph.2022.105210_bib6","unstructured":"de Witte WEA, Danhof M, van der Graaf PH, de Lange ECM. In Vivo Target Residence Time and Kinetic Selectivity: the Association Rate Constant as Determinant. (1873-3735 (Electronic))."},{"issue":"10","key":"10.1016\/j.yrtph.2022.105210_bib7","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"46","key":"10.1016\/j.yrtph.2022.105210_bib8","doi-asserted-by":"crossref","first-page":"15774","DOI":"10.1021\/jacs.8b08048","article-title":"Binding kinetics survey of the drugged kinome","volume":"140","author":"Georgi","year":"2018","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"10.1016\/j.yrtph.2022.105210_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/pharmaceutics13060778","article-title":"Physiologically based pharmacokinetic modelling of cabozantinib to simulate enterohepatic recirculation, drug-drug interaction with rifampin and liver impairment","volume":"13","author":"Gerner","year":"2021","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.yrtph.2022.105210_bib10","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/cpt.1360","article-title":"Clinical aspects of transporter-mediated drug-drug interactions","volume":"105","author":"Gessner","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.yrtph.2022.105210_bib11","unstructured":"Grimwood S, Hartig PR. Target Site Occupancy: Emerging Generalizations from Clinical and Preclinical Studies. (1879-016X (Electronic))."},{"key":"10.1016\/j.yrtph.2022.105210_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejps.2017.01.033","article-title":"Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies","volume":"101","author":"Hagan","year":"2017","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"10","key":"10.1016\/j.yrtph.2022.105210_bib13","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/psp4.12343","article-title":"PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin","volume":"7","author":"Hanke","year":"2018","journal-title":"Cpt-Pharmacomet Syst Pharmacol."},{"issue":"2","key":"10.1016\/j.yrtph.2022.105210_bib14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cpt.2125","article-title":"Physiologically-based pharmacokinetic modeling in renal and hepatic impairment populations: a pharmaceutical industry perspective","volume":"110","author":"Heimbach","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.yrtph.2022.105210_bib15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40262-013-0117-y","article-title":"Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations","volume":"53","author":"Hsu","year":"2014","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.yrtph.2022.105210_bib20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1124\/dmd.113.055475","article-title":"6\u03b2-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3\/SLC22A8, in healthy subjects","volume":"42","author":"Imamura","year":"2014","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.yrtph.2022.105210_bib21","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.clpt.6100038","article-title":"Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers","volume":"81","author":"Lau","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.yrtph.2022.105210_bib22","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1021\/acscentsci.9b00770","article-title":"Drug-target residence time affects in vivo target occupancy through multiple pathways","volume":"5","author":"Lee","year":"2019","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.yrtph.2022.105210_bib23","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1002\/jcph.1713","article-title":"A physiological approach to pharmacokinetics in chronic kidney disease","volume":"60","author":"Malik","year":"2020","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.yrtph.2022.105210_bib24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1124\/dmd.114.062877","article-title":"Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues","volume":"43","author":"Margaillan","year":"2015","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.yrtph.2022.105210_bib25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40265-017-0723-3","article-title":"Baricitinib: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.yrtph.2022.105210_bib26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.clinthera.2011.11.011","article-title":"Pharmacokinetics of vandetanib: three phase I studies in healthy subjects","volume":"34","author":"Martin","year":"2012","journal-title":"Clin. Therapeut."},{"issue":"9","key":"10.1016\/j.yrtph.2022.105210_bib27","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/1060028019839650","article-title":"Baricitinib: the second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis","volume":"53","author":"Mogul","year":"2019","journal-title":"Ann. Pharmacother."},{"issue":"8","key":"10.1016\/j.yrtph.2022.105210_bib28","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1124\/dmd.111.039115","article-title":"Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats","volume":"39","author":"Naud","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.yrtph.2022.105210_bib29","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-8-5","article-title":"Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib","volume":"9","author":"Nezamololama","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.yrtph.2022.105210_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100020","article-title":"Drug-drug interactions in polypharmacy patients: the impact of renal impairment","volume":"2","author":"Papotti","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discover."},{"key":"10.1016\/j.yrtph.2022.105210_bib31","first-page":"381","article-title":"Enzymatic slow-binding inhibition","volume":"68","author":"Pawelczak","year":"2014","journal-title":"Chemik"},{"issue":"11","key":"10.1016\/j.yrtph.2022.105210_bib32","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1007\/s00204-020-02912-1","article-title":"CYP-associated drug-drug interactions: a mission accomplished?","volume":"94","author":"Pelkonen","year":"2020","journal-title":"Arch. Toxicol."},{"issue":"2","key":"10.1016\/j.yrtph.2022.105210_bib33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/metabo11020075","article-title":"Evaluation of pharmacokinetic drug-drug interactions: a review of the mechanisms, in vitro and in silico approaches","volume":"11","author":"Peng","year":"2021","journal-title":"Metabolites"},{"issue":"6","key":"10.1016\/j.yrtph.2022.105210_bib34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/cts.12486","article-title":"Prediction of transporter-mediated drug-drug interactions for baricitinib","volume":"10","author":"Posada","year":"2017","journal-title":"CTS-Clin. Transl. Sci."},{"issue":"12","key":"10.1016\/j.yrtph.2022.105210_bib35","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1124\/dmd.116.072066","article-title":"Abundance of drug transporters in the human kidney cortex as quantified by quantitative targeted proteomics","volume":"44","author":"Prasad","year":"2016","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.yrtph.2022.105210_bib36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1023\/B:PHAM.0000012153.71993.cb","article-title":"Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases","volume":"21","author":"Sakurai","year":"2004","journal-title":"Pharm. Res. (N. Y.)"},{"issue":"2","key":"10.1016\/j.yrtph.2022.105210_bib37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cpt.917","article-title":"Harnessing meta-analysis to refine an oncology patient population for physiology-based pharmacokinetic modeling of drugs","volume":"103","author":"Schwenger","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.yrtph.2022.105210_bib38","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1124\/dmd.117.075242","article-title":"Microsomal and cytosolic scaling factors in dog and human kidney cortex and application for in vitro-in vivo extrapolation of renal metabolic clearance","volume":"45","author":"Scotcher","year":"2017","journal-title":"Drug Metab. Dispos."},{"issue":"12","key":"10.1016\/j.yrtph.2022.105210_bib39","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1124\/dmd.113.053215","article-title":"Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance","volume":"41","author":"Shen","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"12","key":"10.1016\/j.yrtph.2022.105210_bib40","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/jcph.354","article-title":"The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers","volume":"54","author":"Shi","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.yrtph.2022.105210_bib41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jbi.2019.103336","article-title":"PharmActa: personalized pharmaceutical care eHealth platform for patients and pharmacists","volume":"100","author":"Spanakis","year":"2019","journal-title":"J. Biomed. Inf."},{"issue":"10","key":"10.1016\/j.yrtph.2022.105210_bib42","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s40262-018-0650-9","article-title":"Complex drug-drug-gene-disease interactions involving cytochromes P450: systematic review of published case reports and clinical perspectives","volume":"57","author":"Storelli","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.yrtph.2022.105210_bib43","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1002\/jcph.1765","article-title":"Drug-drug interaction studies with oral contraceptives: pharmacokinetic\/pharmacodynamic and study design considerations","volume":"60","author":"Sun","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.yrtph.2022.105210_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01553","article-title":"Butyric acid increases the therapeutic effect of EHLJ7 on ulcerative colitis by inhibiting JAK2\/STAT3\/SOCS1 signaling pathway","volume":"10","author":"Tang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yrtph.2022.105210_bib45","series-title":"Center for Drug Evaluation and Research, Guidance for Industry","year":"2016"},{"issue":"8","key":"10.1016\/j.yrtph.2022.105210_bib46","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40264-020-00938-z","article-title":"Critical assessment of pharmacokinetic drug-drug interaction potential of tofacitinib, baricitinib and upadacitinib, the three approved Janus kinase inhibitors for rheumatoid arthritis treatment","volume":"43","author":"Veeravalli","year":"2020","journal-title":"Drug Saf."},{"issue":"5","key":"10.1016\/j.yrtph.2022.105210_bib47","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cpt.1699","article-title":"Quantitative proteomics and mechanistic modeling of transporter-mediated disposition in nonalcoholic fatty liver disease","volume":"107","author":"Vildhede","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.yrtph.2022.105210_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/biom9090493","article-title":"Utilizing the combination of binding kinetics and micro-pharmacokinetics link in vitro \u03b1-glucosidase inhibition to in vivo target occupancy","volume":"9","author":"Wang","year":"2019","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.yrtph.2022.105210_bib49","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/jcph.1784","article-title":"Applications of physiologically based pharmacokinetic modeling of rivaroxaban-renal and hepatic impairment and drug-drug interaction potential","volume":"61","author":"Willmann","year":"2021","journal-title":"J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.yrtph.2022.105210_bib50","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/j.xphs.2017.04.045","article-title":"In vitro-in vivo extrapolation of metabolism- and transporter-mediated drug-drug interactions-overview of basic prediction methods","volume":"106","author":"Yoshida","year":"2017","journal-title":"J. Pharmacol. Sci."},{"issue":"23","key":"10.1016\/j.yrtph.2022.105210_bib51","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Yung-Chi","year":"1973","journal-title":"Biochem. Pharmacol."},{"issue":"7","key":"10.1016\/j.yrtph.2022.105210_bib52","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1128\/AAC.02414-14","article-title":"Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearance of the conjugated metabolites","volume":"58","author":"Zhong","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.yrtph.2022.105210_bib53","article-title":"Drug-drug interactions at organic cation transporter 1","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230022000976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230022000976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:33:14Z","timestamp":1759494794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230022000976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":48,"alternative-id":["S0273230022000976"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2022.105210","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically based pharmacokinetic combined JAK2 occupancy modelling to simulate PK and PD of baricitinib with kidney transporter inhibitors and in patients with hepatic\/renal impairment","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2022.105210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105210"}}